VIGORITA, Maria
 Distribuzione geografica
Continente #
EU - Europa 3.005
NA - Nord America 2.808
AS - Asia 1.439
SA - Sud America 479
AF - Africa 38
OC - Oceania 2
Totale 7.771
Nazione #
US - Stati Uniti d'America 2.759
RU - Federazione Russa 1.501
SG - Singapore 609
CN - Cina 458
BR - Brasile 416
IE - Irlanda 401
SE - Svezia 391
UA - Ucraina 198
DE - Germania 163
HK - Hong Kong 143
FI - Finlandia 77
FR - Francia 72
GB - Regno Unito 70
IT - Italia 66
IN - India 54
VN - Vietnam 50
CA - Canada 23
AR - Argentina 22
PL - Polonia 15
UZ - Uzbekistan 15
MX - Messico 14
ZA - Sudafrica 13
BD - Bangladesh 12
IQ - Iraq 12
IR - Iran 12
TR - Turchia 10
BE - Belgio 8
CO - Colombia 8
MA - Marocco 8
EC - Ecuador 7
ID - Indonesia 7
VE - Venezuela 7
CZ - Repubblica Ceca 6
ES - Italia 6
JO - Giordania 6
PK - Pakistan 6
PY - Paraguay 6
CL - Cile 5
GR - Grecia 5
JP - Giappone 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
KE - Kenya 4
PT - Portogallo 4
RS - Serbia 4
SA - Arabia Saudita 4
BO - Bolivia 3
GT - Guatemala 3
JM - Giamaica 3
LB - Libano 3
MY - Malesia 3
NL - Olanda 3
NO - Norvegia 3
OM - Oman 3
UY - Uruguay 3
AL - Albania 2
AT - Austria 2
AU - Australia 2
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
DZ - Algeria 2
EG - Egitto 2
ET - Etiopia 2
IL - Israele 2
LT - Lituania 2
NG - Nigeria 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BY - Bielorussia 1
CG - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
HR - Croazia 1
HU - Ungheria 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
PE - Perù 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RO - Romania 1
SR - Suriname 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
TW - Taiwan 1
TZ - Tanzania 1
Totale 7.771
Città #
Moscow 443
Dublin 400
Jacksonville 352
Ashburn 341
Dallas 334
Singapore 328
Chandler 275
Nyköping 265
Dearborn 188
Beijing 167
Hong Kong 143
San Jose 118
The Dalles 79
Cambridge 61
Medford 61
Princeton 61
Los Angeles 57
Lauterbourg 52
Ann Arbor 45
Boardman 40
Des Moines 37
Buffalo 33
São Paulo 33
Council Bluffs 31
New York 30
Munich 28
Jinan 26
Ho Chi Minh City 24
Tianjin 23
Lancaster 21
San Mateo 21
Guangzhou 14
Warsaw 14
Chennai 13
Phoenix 13
Tashkent 13
Belo Horizonte 12
Haikou 12
Montreal 12
Rio de Janeiro 12
Santa Clara 12
Turku 12
Woodbridge 12
Frankfurt am Main 11
Ardabil 10
Brasília 10
Hanoi 10
Shenyang 10
Wilmington 10
Nanchang 9
Orem 9
Brussels 8
Johannesburg 8
Nanjing 8
Stockholm 8
Atlanta 7
Denver 7
Houston 7
Seattle 7
Bremen 6
Changsha 6
Contagem 6
Curitiba 6
Guarulhos 6
Hebei 6
London 6
Milan 6
Redondo Beach 6
San Francisco 6
Turin 6
Amman 5
Asunción 5
Baghdad 5
Boston 5
Brno 5
Campinas 5
Dhaka 5
Fuzhou 5
Goiânia 5
Hangzhou 5
Monmouth Junction 5
Ningbo 5
Pune 5
Shanghai 5
Sorocaba 5
Taiyuan 5
Taizhou 5
Tokyo 5
Washington 5
Zhengzhou 5
Augusta 4
Brooklyn 4
Helsinki 4
Indore 4
Istanbul 4
Louisville 4
Mumbai 4
New Delhi 4
Norwalk 4
Praia Grande 4
Totale 4.613
Nome #
5-Arylidene-2-imino-4-thiazolidinones: Design and synthesis of novel anti-inflammatory agents 252
2/4-Substituted-9-fluorenones and their O-glucosides as potential immunomodulators and anti-herpes simplex virus-2 agents.Part 5 208
5-Arylidene-2,4-thiazolidinediones as inhibitors of protein tyrosine phosphatases 188
9-fluorenon-4-carboxamides: synthesis, conformational analysis, anti-HSV-2, and immunomodulatory evaluation. Note II 188
2-Phenylimino-5-arylidene-4-thiazolidinones. Synthesis and pharmacological evaluation on IL-1induced alteration in cartilage metabolism. 182
5-Ariliden-2,4-tiazolidindioni inibitori dell'aldoso reduttasi e potenziali agenti antiiperglicemizzanti 175
4-Carbossiamido-9-fluorenoni: proprietà anti-HSV-2 e immunostimolanti 175
5-Arylidene-2,4-thiazolidinediones. Synthesis and in vitro activity as ALR2 inhibitors 174
FLUOROCONTAINING D-CYCLOSERINES - SYNTHESIS AND INVITRO EVALUATION OF ANTIMICROBIAL AND ANTIVIRAL ACTIVITIES 174
5-Ariliden-2,4-tiazolidindioni potenziali antidiabetici inibitori della protein tirosina fosfatasi 1B 170
Configurational assignments of the diastereomers of 3,3 '-(1,2- ethanediyl)bis[2-(3-fluorophenyl)-5-methyl-4-thiazolidinone] derivative with four stereogenic centers 165
5-Arilmetilen- e 5-arilmetil-2,4-tiazolidindioni inibitori dell'aldoso reduttasi 163
2 '-[1-(4-Fluorophenyl)ethyl]isonicotino-kappa N-hydrazide- cyanoborane 162
Antimycobacterial in vitro activity of cobalt(II) isonicotinoylhydrazone complexes. Part 10 159
Evaluation of in vitro aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. 158
Bistiazolidinoni chirali: SARs molecular modeling, inibizione COX-I/COX-2 158
Facile biocatalytic access to 9-fluorenylmethyl polyglycosides: evaluation of antiviral activity on immunocompetent cells 157
Design and synthesis of 5-arylidene-2-imino-4-thiazolidinones Celecoxib analogues as antiinflammatory and anticancer agents 156
Biocatalysed synthesis of beta-O-glucosides from 9-fluorenon-2-carbohydroxyesters. Part 3: IFN-inducing and anti-HSV-2 properties 156
Design and synthesis of DNA-intercalating 9-fluoren-beta-O-glycosides as potential IFN-inducers, and antiviral and cytostatic agents 148
Chiral 3,3 '-(1,2-ethanediyl)-bis[2-(3,4-dimethoxyphenyl)-4- thiazolidinones] with anti-inflammatory activity. Part 11: Evaluation of COX-2 selectivity and modelling 148
5-Arylidene-2,4-thiazolidinediones as protein tyrosine phosphatases inhibitors 146
Cyanoborane adducts of isonicotinohydrazides. Synthesis and evaluation of antineoplastic activity. 146
Nickel(II) 2,6-diacetylpyridine bis(isonicotinoylhydrazonate) and bis(benzoylhydrazonate) complexes: Structure and antimycobacterial evaluation. Part XI 132
Modeling and biological evaluation of 3.3 '-(1,2- ethanediyl)bis[2-(4-methoxyphenyl)-thiazolidin-4-one], a new synthetic cyclooxygenase-2 inhibitor 131
Synthesis and in vitro evaluation of 5-arylidene-3-hydroxyalkyl-2-phenylimino-4-thiazolidinones with antidegenerative activity on human chondrocyte cultures 124
In vitro antiproliferative activity against human colon cancer cell lines of representative 4-thiazolidinones. Part I 123
Synthesis and aldose reductase inhibitory activity of 5-arylidene-2,4-thiazolidinediones 122
Synthesis and antiinflammatory, analgesic activity of 3,3’-(1,2-ethanediyl)-bis[2-aryl-4-thiazolidinone] chiral compounds. Part 10. 118
Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors 117
Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9 117
In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones 117
INH-related hydrazides and cyanoboranes with antimycobacterial in vitro activity 115
Relazioni Struttura/Attività e molecular modelling di 5-ariliden-2,4-tiazolidindioni inibitori dell'aldoso reduttasi 109
In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: Part 14 108
Tilorone analogues with IFN-inducing and anti-HSV-2 activity 105
Lipophilic analogs of isoniazid with antiproliferative in vitro activity - VIII 105
Synthesis and in vivo/ex vivo antiinflammatory evaluation of 5-arylidene-2-imino-4-thiazolidinones as potential celecoxib analogues 105
Evaluation of COX-2 selectivity and molecular modeling of novel 3,3'-(1,2-ethanediyl)bis-[2-(methoxyphenyl)-thiazolidin-4-ones] with antiinflammatory activity 104
Progettazione, sintesi e attivita' farmacologica di nuovi derivati fluorenonici intercalanti 102
Inibitori COX-2 selettivi a struttura tiazolidinonica. Valutazione dell'attività citotossica su linee cellulari di carcinoma del colon umano 102
Progettazione e sintesi di derivati fluorenici intercalanti ad attività IFN-inducente ed anti-HSV-2 102
In vitro antimycobacterial activities of 2 '-monosubstituted isonicotinohydrazides and their cyanoborane adducts 102
Fluoren b-O-glucosides: biosynthesis and DNA-intercalating activity evaluation 101
Halogenated isoniazid derivatives .6. Evaluation of anti-HSV-1 and anti-HIV-1 in vitro activities of fluorinated analogues 101
Sintesi, attività e molecular modelling di 5-ariliden-2,4-tiazolidindioni inibitori della PTP1B. 99
In vitro Antimycobacterial Activity of Isoniazid-related Metalchelates 98
Nuclear magnetic resonance of psychotherapeutic agents. IV. Conformational analysis of 2,3-dihydro.1H-1,4-benzodiazepines 97
Nuclear magnetic resonance of 1,4-benzodiazepines. II. Stereochemistry of 1,3-dihydro-2H-1,4-benzodiazepin-2-ones by lanthanide shift reagents 97
Tetraplex DNA specific ligand based on the fluorenone-carboxamide scaffold. 95
Synthesis and in vitro antimicrobial and antitumoral screening of novel lipophilic isoniazid analogues. VI. 95
Nuclear magnetic resonance spectra of psychotherapeutic agents. V. Conformational analysis of 1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-ones 92
Sintesi, attività in vitro e SARs di 2,4-tiazolidindioni inibitori dell'aldoso reduttasi 91
Risonanza magnetica nucleare di 1,4-benzodiazepine. Accoppiamento attraverso lo spazio di 2,3-diidro-1H-1,4-benzodiazepine 1-sostituite 91
Isonicotinoilidrazoni fluorurati: reattività ed attività antimicobatterica ed anti-HIV 89
Isonicotinoilidrazoni: reattività con diazometano ed attività antimicobatterica ed anti-HIV 86
In Vitro Aldose Reductase Inhibitory Activity of 5-Benzyl-2,4-thiazolidinediones 85
Metal(II) complexes with isoniazid analogues: synthesis and pharmacological activity 81
Metalchelati di aroilidrazoni. Sintesi e valutazione dell'attività antitubercolare 75
Nuclear magnetic resonance spectra of psychotherapeutic agents. III. Stereochemistry of 1-methyl5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-2,4-diones 75
Reattività di isonicotinoilidrazoni con diazometano 75
Totale 7.791
Categoria #
all - tutte 25.244
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.244


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 0 0 11
2021/2022413 6 94 3 10 22 0 27 14 6 27 70 134
2022/20231.161 94 130 57 100 76 118 27 57 476 9 17 0
2023/2024204 16 34 32 13 24 42 1 13 0 3 0 26
2024/20251.093 13 9 19 79 42 33 42 212 297 65 107 175
2025/20263.540 180 318 296 241 241 788 438 417 403 128 64 26
Totale 7.791